Literature DB >> 22758909

Altered expression and splicing of Ca(2+) metabolism genes in myotonic dystrophies DM1 and DM2.

A Vihola1, M Sirito, L L Bachinski, O Raheem, M Screen, T Suominen, R Krahe, B Udd.   

Abstract

AIMS: Myotonic dystrophy types 1 and 2 (DM1 and DM2) are multisystem disorders caused by similar repeat expansion mutations, with similar yet distinct clinical features. Aberrant splicing of multiple effector genes, as well as dysregulation of transcription and translation, has been suggested to underlie different aspects of the complex phenotypes in DM1 and DM2. Ca(2+) plays a central role in both muscle contraction and control of gene expression, and recent expression profiling studies have indicated major perturbations of the Ca(2+) signalling pathways in DM. Here we have further investigated the expression of genes and proteins involved in Ca(2+) metabolism in DM patients, including Ca(2+) channels and Ca(2+) binding proteins.
METHODS: We used patient muscle biopsies to analyse mRNA expression and splicing of genes by microarray expression profiling and RT-PCR. We studied protein expression by immunohistochemistry and immunoblotting.
RESULTS: Most of the genes studied showed mRNA up-regulation in expression profiling. When analysed by immunohistochemistry the Ca(2+) release channel ryanodine receptor was reduced in DM1 and DM2, as was calsequestrin 2, a sarcoplasmic reticulum lumen Ca(2+) storage protein. Abnormal splicing of ATP2A1 was more pronounced in DM2 than DM1.
CONCLUSIONS: We observed abnormal mRNA and protein expression in DM affecting several proteins involved in Ca(2+) metabolism, with some differences between DM1 and DM2. Our protein expression studies are suggestive of a post-transcriptional defect(s) in the myotonic dystrophies.
© 2012 The Authors. Neuropathology and Applied Neurobiology © 2012 British Neuropathological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22758909      PMCID: PMC3882430          DOI: 10.1111/j.1365-2990.2012.01289.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  62 in total

1.  Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane.

Authors:  L Zhang; J Kelley; G Schmeisser; Y M Kobayashi; L R Jones
Journal:  J Biol Chem       Date:  1997-09-12       Impact factor: 5.157

2.  cDNA cloning, functional expression, and mRNA tissue distribution of a third organellar Ca2+ pump.

Authors:  S E Burk; J Lytton; D H MacLennan; G E Shull
Journal:  J Biol Chem       Date:  1989-11-05       Impact factor: 5.157

3.  Proximal myotonic dystrophy--a family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes?

Authors:  B Udd; R Krahe; C Wallgren-Pettersson; B Falck; H Kalimo
Journal:  Neuromuscul Disord       Date:  1997-06       Impact factor: 4.296

4.  Adult forms of the Ca2+ATPase of sarcoplasmic reticulum. Expression in developing skeletal muscle.

Authors:  C J Brandl; S deLeon; D R Martin; D H MacLennan
Journal:  J Biol Chem       Date:  1987-03-15       Impact factor: 5.157

5.  Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene.

Authors:  M Mahadevan; C Tsilfidis; L Sabourin; G Shutler; C Amemiya; G Jansen; C Neville; M Narang; J Barceló; K O'Hoy
Journal:  Science       Date:  1992-03-06       Impact factor: 47.728

6.  An unstable triplet repeat in a gene related to myotonic muscular dystrophy.

Authors:  Y H Fu; A Pizzuti; R G Fenwick; J King; S Rajnarayan; P W Dunne; J Dubel; G A Nasser; T Ashizawa; P de Jong
Journal:  Science       Date:  1992-03-06       Impact factor: 47.728

7.  Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis.

Authors:  Nikolai A Timchenko; Roma Patel; Polina Iakova; Zong-Jin Cai; Ling Quan; Lubov T Timchenko
Journal:  J Biol Chem       Date:  2004-01-13       Impact factor: 5.157

Review 8.  Calsequestrin and the calcium release channel of skeletal and cardiac muscle.

Authors:  N A Beard; D R Laver; A F Dulhunty
Journal:  Prog Biophys Mol Biol       Date:  2004-05       Impact factor: 3.667

9.  Tissue-specific and developmentally regulated alternative splicing in mouse skeletal muscle ryanodine receptor mRNA.

Authors:  A Futatsugi; G Kuwajima; K Mikoshiba
Journal:  Biochem J       Date:  1995-01-15       Impact factor: 3.857

10.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

Authors:  J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

View more
  13 in total

Review 1.  The neonatal sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA1b): a neglected pump in scope.

Authors:  Ernő Zádor; Magdolna Kósa
Journal:  Pflugers Arch       Date:  2014-12-18       Impact factor: 3.657

2.  Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2.

Authors:  Erek M Lam; Paul W Shepard; Erik K St Louis; Lucas G Dueffert; Nancy Slocumb; Stuart J McCarter; Michael H Silber; Bradley F Boeve; Eric J Olson; Virend K Somers; Margherita Milone
Journal:  Neurology       Date:  2013-06-07       Impact factor: 9.910

3.  The neonatal sarcoplasmic reticulum Ca2+-ATPase gives a clue to development and pathology in human muscles.

Authors:  Magdolna Kósa; Kitti Brinyiczki; Philip van Damme; Nathalie Goemans; Károly Hancsák; Luca Mendler; Ernő Zádor
Journal:  J Muscle Res Cell Motil       Date:  2014-12-09       Impact factor: 2.698

4.  Endurance exercise leads to beneficial molecular and physiological effects in a mouse model of myotonic dystrophy type 1.

Authors:  Lydia Sharp; Diana C Cox; Thomas A Cooper
Journal:  Muscle Nerve       Date:  2019-10-23       Impact factor: 3.217

5.  Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I.

Authors:  Marielle Brockhoff; Nathalie Rion; Kathrin Chojnowska; Tatiana Wiktorowicz; Christopher Eickhorst; Beat Erne; Stephan Frank; Corrado Angelini; Denis Furling; Markus A Rüegg; Michael Sinnreich; Perrine Castets
Journal:  J Clin Invest       Date:  2017-01-09       Impact factor: 14.808

6.  Genome wide identification of aberrant alternative splicing events in myotonic dystrophy type 2.

Authors:  Alessandra Perfetti; Simona Greco; Pasquale Fasanaro; Enrico Bugiardini; Rosanna Cardani; Jose M Garcia-Manteiga; Jose M Garcia Manteiga; Michela Riba; Davide Cittaro; Elia Stupka; Giovanni Meola; Fabio Martelli
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

Review 7.  Can Human Pluripotent Stem Cell-Derived Cardiomyocytes Advance Understanding of Muscular Dystrophies?

Authors:  Spandan Kalra; Federica Montanaro; Chris Denning
Journal:  J Neuromuscul Dis       Date:  2016-08-30

8.  Functional KCa1.1 channels are crucial for regulating the proliferation, migration and differentiation of human primary skeletal myoblasts.

Authors:  Rajeev B Tajhya; Xueyou Hu; Mark R Tanner; Redwan Huq; Natee Kongchan; Joel R Neilson; George G Rodney; Frank T Horrigan; Lubov T Timchenko; Christine Beeton
Journal:  Cell Death Dis       Date:  2016-10-20       Impact factor: 8.469

9.  Investigation of the molecular mechanisms underlying myotonic dystrophy types 1 and 2 cataracts using microRNA‑target gene networks.

Authors:  Dewang Shao; Xiaoquan Zhu; Wei Sun; Lu Huo; Wei Chen; Hua Wang; Bing Liu; Peng Pan
Journal:  Mol Med Rep       Date:  2017-07-21       Impact factor: 2.952

10.  Characterization of Iron Accumulation in Deep Gray Matter in Myotonic Dystrophy Type 1 and 2 Using Quantitative Susceptibility Mapping and R2* Relaxometry: A Magnetic Resonance Imaging Study at 3 Tesla.

Authors:  Sevda Ates; Andreas Deistung; Ruth Schneider; Christian Prehn; Carsten Lukas; Jürgen R Reichenbach; Christiane Schneider-Gold; Barbara Bellenberg
Journal:  Front Neurol       Date:  2019-12-13       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.